• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vaxcyte, Inc. - Common Stock (NQ:PCVX)

    50.22 +2.92 (+6.17%)
    Streaming Delayed Price Updated: 3:21 PM EDT, May 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 840,367
    Open 47.74
    Bid (Size) 50.15 (100)
    Ask (Size) 50.22 (200)
    Prev. Close 47.30
    Today's Range 47.10 - 50.25
    52wk Range 29.08 - 65.00
    Shares Outstanding 93,706,790
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
    Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
    This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +8.1%
    +8.1%
    1 Month
    -15.9%
    -15.9%
    3 Month
    -16.7%
    -16.7%
    6 Month
    +2.0%
    +2.0%
    1 Year
    +58.3%
    +58.3%

    More News

    Read More
    News headline image
    Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗
    Via Chartmill
    News headline image
    What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
    Via The Motley Fool
    News headline image
    Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
    Via MarketMinute
    Topics Artificial Intelligence Economy Supply Chain
    News headline image
    Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Announces Pricing of $550 Million Public Offering
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte's Chief Technical Ops Officer Sells Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
    From Vaxcyte, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Vaxcyte, Inc. - Common Stock publicly traded?
    Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
    What exchange does Vaxcyte, Inc. - Common Stock trade on?
    Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
    The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
    What is the current price of Vaxcyte, Inc. - Common Stock?
    The current price of Vaxcyte, Inc. - Common Stock is 50.22
    When was Vaxcyte, Inc. - Common Stock last traded?
    The last trade of Vaxcyte, Inc. - Common Stock was at 05/26/26 03:21 PM ET
    What is the market capitalization of Vaxcyte, Inc. - Common Stock?
    The market capitalization of Vaxcyte, Inc. - Common Stock is 4.71B
    How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
    Vaxcyte, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.